Incyte

Phone: +1 855-446-2983; +1 855-446-2983; +1 302-498-6700

E-mail: bd@incyte.com

Web: https://www.incyte.com

Type	Public company
Traded as	Nasdaq: INCY S&P 500 component
Industry	pharmaceutical company
Founded	2002 (2002)
Headquarters	Wilmington, Delaware, U.S.
Key people	Hervé Hoppenot (CEO, chairman & president)
Revenue	US$2.99 billion (2021)
Operating income	US$586 million (2021)
Net income	US$949 million (2021)
Total assets	US$4.93 billion (2021)
Total equity	US$3.77 billion (2021)
Number of employees	2,094 (December 2021)
Website	incyte.com

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. Today, we employ approximately 1500 people and have operations in the U.S., Europe and Japan. Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity. The commitment of our talented team of world-class scientists to continued scientific excellence has enabled us to identify new molecules, decipher new pathways and develop first-in-class and best-in-class medicines.

For detailed contact information visit location pages below.